A randomised, multicentre accelerated radiotherapy study of dose escalated intensity-modulated radiotherapy versus standard dose intensity-modulated radiotherapy in patients receiving treatment for locally advanced laryngeal and hypopharyngeal cancers.
Disease site: Head and neck cancer
Treatment modality: Radiotherapy
Status: In follow up
ART DECO is a phase III, multicentre, randomised controlled trial to determine the potential of dose escalated intensity-modulated radiotherapy (IMRT) to improve locoregional failure free rate and laryngeal preservation in patients with locally advanced laryngeal and hypopharyngeal cancers, without increasing the incidence of severe acute and late toxicities to unacceptable levels.
ART DECO recruited 276 patients and closed to recruitment in October 2015. Participants are now being followed up for at least a further 5 years. In ART DECO, patients received either dose escalated IMRT or standard dose IMRT. Dose escalated IMRT delivered 67.2 Gy in 28 fractions to the involved site and nodal groups, and 56 Gy in 28 fractions to nodal areas at risk of harbouring microscopic disease; standard dose IMRT was lower.
Chief Investigator: Professor Christopher Nutting, The Royal Marsden NHS Foundation Trust
ICR-CTSU Scientific Lead: Dr Emma Hall
Trial management contact: [email protected]
Sponsor: The Royal Marsden NHS Foundation Trust
Funding: Cancer Research UK (CRUK/10/018)
Further information including recruitment progress is available from the UK Clinical Trials Gateway.
A plain English summary is available from Cancer Research UK.
Publications and presentations
There have been no presentations or publications to date